×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CLDX – celldex therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CLDX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/11
10:10 am
cldx
Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Barclays PLC from $25.00 to $21.00. They now have an "underweight" rating on the stock.
Medium
Report
Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Barclays PLC from $25.00 to $21.00. They now have an "underweight" rating on the stock.
11/10
04:01 pm
cldx
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/10
08:01 am
cldx
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
Low
Report
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
11/7
08:01 am
cldx
Celldex to Present at Upcoming Investor Conferences
Low
Report
Celldex to Present at Upcoming Investor Conferences
11/6
08:00 am
cldx
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
Medium
Report
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
11/6
08:00 am
cldx
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients wi
Medium
Report
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients wi
10/30
04:01 pm
cldx
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
Low
Report
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
10/21
08:03 am
cldx
Celldex Therapeutics (NASDAQ:CLDX) is now covered by analysts at Mizuho. They set an "outperform" rating and a $48.00 price target on the stock.
Low
Report
Celldex Therapeutics (NASDAQ:CLDX) is now covered by analysts at Mizuho. They set an "outperform" rating and a $48.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/10/2025
04:01 pm
CLDX
celldex therapeutics, inc.
MISS
Report
7.5%
celldex therapeutics, inc.
5/8/2025
04:01 pm
CLDX
celldex therapeutics, inc.
MISS
Report
-6.1%
celldex therapeutics, inc.
2/27/2025
04:01 pm
CLDX
celldex therapeutics, inc.
BEAT
Report
1.3%
celldex therapeutics, inc.
2/27/2025
04:01 pm
CLDX
celldex therapeutics, inc.
BEAT
Report
1.3%
celldex therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/4
04:04 pm
cldx
Form 144 Celldex Therapeutics, Filed by: Jimenez Freddy A.
Low
Report
Form 144 Celldex Therapeutics, Filed by: Jimenez Freddy A.
11/17
04:17 pm
cldx
Form 4 Celldex Therapeutics, For: Nov 13 Filed by: Wright Richard M.
Low
Report
Form 4 Celldex Therapeutics, For: Nov 13 Filed by: Wright Richard M.
11/14
07:59 pm
cldx
Form SCHEDULE 13G Celldex Therapeutics, Filed by: Bellevue Group AG
Low
Report
Form SCHEDULE 13G Celldex Therapeutics, Filed by: Bellevue Group AG
11/14
05:09 pm
cldx
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Commodore Capital LP
Low
Report
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Commodore Capital LP
11/14
12:21 pm
cldx
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Low
Report
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/12
04:12 pm
cldx
Form 4 Celldex Therapeutics, For: Nov 10 Filed by: Lawver Teri L
Low
Report
Form 4 Celldex Therapeutics, For: Nov 10 Filed by: Lawver Teri L
11/12
04:06 pm
cldx
Form 3 Celldex Therapeutics, For: Nov 10 Filed by: Lawver Teri L
Low
Report
Form 3 Celldex Therapeutics, For: Nov 10 Filed by: Lawver Teri L
11/10
04:07 pm
cldx
Form 10-Q Celldex Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Celldex Therapeutics, For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/20
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
30.1%
4/28 Form DEF 14A Celldex Therapeutics, For: Jun 18 9.6%
3/26 Q4/2019 12/31/2019 EPS -0.640 ZacksConsensus N/A ActVsEst N/A - N/A 3.4%
8/7 Q2/2019 6/30/2019 EPS -0.840 ZacksConsensus -1.170 ActVsEst 0.330 - Beat 2.3%
6/21 Form S-8 Celldex Therapeutics, 2.0%
10/2 Celldex Therapeutics Announces Upcoming Data Presentations 1.9%
10/9 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 1.4%
12/23 Is Celldex Therapeutics, Inc. (CLDX) A Good Stock To Buy? [Yahoo! Finance News] 1.3%
2/12 Form SC 13G Celldex Therapeutics, Filed by: RENAISSANCE TECHNOLOGIES LLC 0.4%
5/24 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 0.4%
4/28 Form DEF 14A Celldex Therapeutics, For: Jun 18 9.6%
3/26 Q4/2019 12/31/2019 EPS -0.640 ZacksConsensus N/A ActVsEst N/A - N/A 3.4%
8/7 Q2/2019 6/30/2019 EPS -0.840 ZacksConsensus -1.170 ActVsEst 0.330 - Beat 2.3%
6/21 Form S-8 Celldex Therapeutics, 2.0%
10/2 Celldex Therapeutics Announces Upcoming Data Presentations 1.9%
10/9 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 1.4%
12/23 Is Celldex Therapeutics, Inc. (CLDX) A Good Stock To Buy? [Yahoo! Finance News] 1.3%
2/12 Form SC 13G Celldex Therapeutics, Filed by: RENAISSANCE TECHNOLOGIES LLC 0.4%
5/24 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 0.4%
TOP News Decliners
3/27
Form 424B5 Celldex Therapeutics,
-12.3%
6/1 Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma -9.6%
11/8 CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study -9.2%
12/6 Form S-3 Celldex Therapeutics, -9.1%
11/12 Q3/2019 9/30/2019 EPS -0.750 ZacksConsensus -0.840 ActVsEst 0.090 - Beat -7.3%
11/18 Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159 -5.9%
3/3 Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program -4.6%
5/7 Q1/2019 3/31/2019 EPS -1.400 ZacksConsensus -1.140 ActVsEst (0.260) - Miss -3.6%
5/8 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was given a new $19.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -2.8%
7/31 Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call -2.8%
6/1 Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma -9.6%
11/8 CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study -9.2%
12/6 Form S-3 Celldex Therapeutics, -9.1%
11/12 Q3/2019 9/30/2019 EPS -0.750 ZacksConsensus -0.840 ActVsEst 0.090 - Beat -7.3%
11/18 Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159 -5.9%
3/3 Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program -4.6%
5/7 Q1/2019 3/31/2019 EPS -1.400 ZacksConsensus -1.140 ActVsEst (0.260) - Miss -3.6%
5/8 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was given a new $19.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -2.8%
7/31 Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call -2.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: